{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
tyrosine
to a specific field?
Status:
Investigational
Source:
NCT03797391: Phase 1/Phase 2 Interventional Recruiting Neoplasms
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03500380: Phase 2/Phase 3 Interventional Active, not recruiting Breast Neoplasms
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03530683: Phase 1 Interventional Terminated Lymphoma
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03526835: Phase 1/Phase 2 Interventional Recruiting Advanced/Metastatic Solid Tumors
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ozuriftamab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT03849651: Phase 2 Interventional Active, not recruiting Acute Lymphoblastic Leukemia (ALL)
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04165993: Phase 2 Interventional Active, not recruiting Metastatic Breast Cancer
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03821233: Phase 1 Interventional Completed HER2-expressing Cancers
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
